BRIEF-Jade Biosciences - Enters Exclusive Worldwide License Agreement With Paragon Therapeutics - SEC Filing

Jade Biosciences, Inc.

Jade Biosciences, Inc.

JBIO

0.00

July 1 (Reuters) - Jade Biosciences Inc JBIO.O:

  • JADE BIOSCIENCES - ENTERS EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH PARAGON THERAPEUTICS - SEC FILING

  • JADE BIOSCIENCES - TO PAY UP TO $22 MILLION IN MILESTONE PAYMENTS TO PARAGON - SEC FILING

  • JADE BIOSCIENCES - TO PAY PARAGON LOW TO MID-SINGLE-DIGIT PERCENTAGE ROYALTIES ON NET SALES OF LICENSED PRODUCTS - SEC FILING

  • JADE BIOSCIENCES - PARAGON BARRED FROM NEW CAMPAIGNS TARGETING LICENSED TARGET FOR AT LEAST FIVE YEARS - SEC FILING

Source text: [ID:n0001193125-26-292704]

Further company coverage: JBIO.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.